The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells
- Br J Haematol. 2015 Jul;170(1):134-8. doi: 10.1111/bjh.13278.
Affiliations
- 1. Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, USA.
- 2. Department of Medicine, Harvard Medical School, Boston, MA, USA.
- 3. Department of Pathology, Boston University Medical Center, Boston, MA, USA.
- 4. Theagenio Cancer Hospital, Thessaloniki, Greece.
- 5. Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, USA. [email protected].
- 6. Department of Medicine, Harvard Medical School, Boston, MA, USA. [email protected].
PMID: 25582069
DOI: 10.1111/bjh.13278
Keywords
ABT-199; BCL2; CXCR4; Ibrutinib; Waldenström macroglobulinemia.
Products
-
Cat. No.Product NameDescriptionTargetResearch Area
-
-